Abnova Taiwan Corp (4133) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of Abnova Taiwan Corp TWD 9.05, price TWD 20.35, upside -55.5%, quality 56 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Abnova Taiwan Corp for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range 20.15 TWD – 78.29 TWD · fair‑value band 8.65 TWD – 9.83 TWD · the 20.35 TWD price screens above the 9.05 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Abnova Taiwan in your weekly email
Every Wednesday you see whether Abnova Taiwan is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Abnova (Taiwan) Corporation engages in the research, development, manufacturing, and sales of monoclonal and multiclonal antibodies, proteins, medical diagnostic instruments, and testing reagents.
Show more
Abnova (Taiwan) Corporation engages in the research, development, manufacturing, and sales of monoclonal and multiclonal antibodies, proteins, medical diagnostic instruments, and testing reagents. The company's products portfolio includes SARS-CoV/CoV-2, DNA, RNA, proteins/peptides, lysates/slides, Ab pairs/kits, Ab arrays, polyclinic antibody, beads/dyes, in situ hybridization products, systems, and automations. It also offers MaxPab, Nano, DNAxPab, monoclonal, polyclonal, recombinant, conjugate, secondary/tag, IHC/pathology, and circulating rare cell antibodies. In addition, the company provides integrated solutions and services, including gene synthesis and cytogenetics; peptide services, protein expression, and conjugations; antibody production and scale up; assay development services; circulating tumor cell and DNA; germline genetic DNA; and FFPE tumor tissue DNA services. It serves academic, research institutions, and pharmaceutical factories. Abnova (Taiwan) Corporation was founded in 2002 and is headquartered in Taipei, Taiwan.
Stock analysis
Abnova Taiwan Corp (4133) currently trades at 20.35 TWD, while our model-based Fair Value estimate is 9.05 TWD, implying the stock looks roughly 124.9% overvalued today.
Show more
Valuation
Bull case: the Asset-Based group reads highest at a median of 13.90 TWD per share, and 0 of the 9 models we run sit above the 20.35 TWD price.
Bear case: the Dividend Discount group reads lowest at 8.61 TWD, and 9 of the 9 models stay below the price. Evidence for this calculation is low.
Scenario range: 8.65 TWD (bear) to 9.83 TWD (bull), the price of 20.35 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 56/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Abnova Taiwan Corp reported revenue of 351M TWD in FY2025 versus 451M TWD in FY2021, a compound −6.1%/yr. Reported net income was −1.1M TWD in FY2025.
Key figures
Market cap 1.2B TWD (≈ $38.8M) · P/S ratio 3.73 · EPS (TTM) −0.0200 TWD · Dividend yield 0.6% · Net margin −0.3% · Return on equity 0.2% · Return on assets (EBIT) 3.4% · Operating margin 11.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
The share trades about 30% below its 52-week high and 1% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −56%, 4133 screens richer than that median.
Fair Value models
Bear 8.65 TWDFair Value 9.05 TWDBull 9.83 TWD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.14/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−1.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−5.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−5.1%
Start year 2020 (pandemic). Over 10 years: −2.5% a year
Revenue growth 17 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.6%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
11.7% (2020) → 4.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 650 stocks
Beats the industry median on 5/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score56 · Above median
Fair Value upside−56% · Below median
Profitability
Return on equity (TTM)0% · Above median
Return on assets1% · Above median
Net margin (TTM)1% · Below median
Operating margin (TTM)12% · Above median
Growth and dividend
Revenue growth−3% · Below median
Dividend yield (TTM)0.6% · Below median
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/S (TTM)0.11× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)0· sector 0
PAST (return on equity)1· sector 0
HEALTH (low debt)100· sector 97
DIVIDEND (yield)11· sector 23
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Abnova Taiwan Corp (4133) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 9.05 TWD versus a price of 20.35 TWD, about −56% upside (overvalued).
What is the fair value of 4133?
Our model-based fair value for Abnova Taiwan Corp is 9.05 TWD (as of Sep 24, 2026), built from audited fundamentals. The current price: 20.35 TWD.
What is the quality score of 4133?
Abnova Taiwan Corp has a Quality Score of 56/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Abnova Taiwan Corp (4133)?
Our model-based price target is the fair value of 9.05 TWD (as of Sep 24, 2026) from 9 valuation models. Cautious scenario 8.65 TWD, optimistic scenario 9.83 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Abnova Taiwan Corp stock forecast for 2026?
Our models put fair value at 9.05 TWD, about −56% upside versus a price of 20.35 TWD (overvalued). Cautious scenario 8.65 TWD, optimistic scenario 9.83 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Abnova Taiwan Corp (4133)?
Abnova Taiwan Corp reported trailing-twelve-month revenue of about 349M TWD (latest available figure, as of Sep 24, 2026).
Does Abnova Taiwan Corp pay a dividend?
Abnova Taiwan Corp currently shows a dividend yield of about 0.55% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of Abnova Taiwan Corp (4133)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Abnova Taiwan Corp it is 9.05 TWD per share (as of Sep 24, 2026), against a price of 20.35 TWD. It is the blended result of 9 valuation models (cash flow, earnings, asset, dividend).
Is Abnova Taiwan Corp stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 4133 trades above its calculated fair value: price 20.35 TWD, fair value 9.05 TWD, a gap of about −56% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 4133?
No. The price is what the market pays today (20.35 TWD); the fair value is what the company's own numbers justify (9.05 TWD). For Abnova Taiwan Corp the two are 11.30 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Abnova Taiwan Corp worth?
The market values Abnova Taiwan Corp at about 1.2B TWD (market capitalisation, as of Sep 24, 2026). Per share that is 20.35 TWD; our models calculate a fair value of 9.05 TWD per share.
What do the bullish and bearish scenarios say about 4133?
Our models span a range for Abnova Taiwan Corp: cautious scenario 8.65 TWD, base 9.05 TWD, optimistic 9.83 TWD per share (as of Sep 24, 2026, price 20.35 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Abnova Taiwan Corp (4133)?
Balance-sheet figures for Abnova Taiwan Corp (as of Sep 24, 2026): return on equity 0.2%. They feed the Quality Score of 56/100, which measures business quality independently of the share price.
How far is 4133 from its 52-week high?
Abnova Taiwan Corp trades at 20.35 TWD, about 30% below its 52-week high of 29.00 TWD and 1% above the low of 20.15 TWD (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of 9.05 TWD is for.
Which stocks are comparable to Abnova Taiwan Corp?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Abnova Taiwan Corp stock attractive at the current price?
The data as of Sep 24, 2026: price 20.35 TWD, calculated fair value 9.05 TWD (−56%), Quality Score 56/100, from 9 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 4133 calculated?
We run Abnova Taiwan Corp through 9 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 9.05 TWD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Abnova Taiwan Corp itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Abnova Taiwan Corp (4133)?
The closing price on Sep 24, 2026 was 20.35 TWD. Our model-based fair value is 9.05 TWD, about −56% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Abnova Taiwan Corp right now?
The price sits above even our optimistic bull case (9.83 TWD). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (56/100) and above fair value, neither a clear bargain nor a standout compounder. The models converge in a tight band (8.65 TWD to 9.83 TWD), unusually little disagreement for a valuation.
Where does the earnings growth of Abnova Taiwan Corp (4133) come from?
Earnings per share at Abnova Taiwan Corp grew −0.4 % a year from 2014 to 2025. Broken into its drivers: revenue per share −2.1 %, EBIT margin −1.2 %, tax rate +0.0 %, residual (interest, one-offs) +2.9 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Abnova Taiwan Corp
How large is the market capitalisation of Abnova Taiwan Corp (4133)?
The market capitalisation of Abnova Taiwan Corp is 1.2B TWD (≈ $38.8M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Abnova Taiwan Corp (4133)?
The price-to-sales ratio of Abnova Taiwan Corp is 3.73 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Abnova Taiwan Corp (4133)?
Earnings per share at Abnova Taiwan Corp are −0.0200 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Abnova Taiwan Corp (4133)?
The dividend yield of Abnova Taiwan Corp is 0.6%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Abnova Taiwan Corp (4133)?
The net margin of Abnova Taiwan Corp is −0.3% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Abnova Taiwan Corp (4133)?
The return on equity (ROE) of Abnova Taiwan Corp is 0.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Abnova Taiwan Corp (4133)?
On an EBIT basis the return on assets of Abnova Taiwan Corp is 3.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Abnova Taiwan Corp (4133)?
The operating margin of Abnova Taiwan Corp is 11.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Abnova Taiwan Corp (4133)?
Revenue at Abnova Taiwan Corp is growing −2.9% versus a year earlier (3y avg −5.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Abnova Taiwan Corp (4133)?
Earnings per share at Abnova Taiwan Corp are growing +25.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Abnova Taiwan Corp (4133) generate?
The free cash flow of Abnova Taiwan Corp is −7.7M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Abnova Taiwan Corp (4133) hold?
Abnova Taiwan Corp holds more cash than debt, 359M TWD net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Abnova Taiwan Corp in the live analysis
One click puts Abnova Taiwan Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
